Key Developments: Elekta publ AB (EKTAb.ST)

EKTAb.ST on Stockholm Stock Exchange

15 Apr 2014
Price Change (% chg)

-1.70kr (-1.96%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Elekta publ AB Appoints Mr. Niklas Savander as President and Chief Executive Officer
Friday, 25 Oct 2013 01:30am EDT 

Elekta publ AB announced that Mr. Niklas Savander has been appointed President and Chief Executive Officer of the Company, effective as of May 1, 2014. He will succeed Mr. Tomas Puusepp, who will continue with Elekta as a working member of its Board of Directors focusing on strategic matters and market-developments per the same date.  Full Article

Private Hospital Group in Spain Expands Radiotherapy Capabilities with Elekta publ AB's Versa HD System
Thursday, 24 Oct 2013 06:00am EDT 

Elekta publ AB announced that HM Hospitales, a private hospital group in Spain, anticipates treating its patients with Elekta's Versa HD system in 2015. Versa HD is a radiation treatment system designed to enhance the management of cancer care and treat a range of tumors throughout the body. The new medical center, Hospital HM Universitario Puerto del Sur, will be connected to the hospital group's first radiation oncology department - Clara Campal Comprehensive Cancer Center at HM Sanchinarro - via Elekta's MOSAIQ Oncology Information System (OIS). Financial details were not disclosed.  Full Article

Elekta publ AB's Esteya Gets FDA 510(k) Clearance
Wednesday, 2 Oct 2013 01:30am EDT 

Elekta publ AB announced that the Company's Esteya has received 510(k) clearance from the US Food and Drug Administration (FDA), enabling medical centers in the United States to offer their patients with skin cancer a new treatment option. The first installations of Esteya in the United States are scheduled to occur in the next few months. Esteya is an electronic brachytherapy system.  Full Article

Elekta publ AB Opens Global Education Center for Oncology and Neuroscience Professionals
Monday, 23 Sep 2013 09:00am EDT 

Elekta publ AB announced that the Company is opening a Global Education Center for Oncology and Neuroscience Professionals at its North American headquarters. The Learning and Innovation Center (LINC) is expected to draw clinicians, researchers and health IT professionals to the city for education, training and collaboration on Elekta’s solutions for treating cancer and brain disorders. The LINC also serves as a tangible introduction to Elekta, with interactive displays highlighting the Company’s achievements in cancer treatment. The 25,000 square foot facility incorporates the latest adult learning principles and technology, and is equipped with actual working systems of virtually every Elekta solution to support hands-on learning.  Full Article

Elekta publ AB's Nucletron Introduces Esteya, Electronic Brachytherapy for Treating Skin Cancer
Saturday, 21 Sep 2013 12:00pm EDT 

Elekta publ AB announced that Nucletron, an Elekta company has launched Esteya, a new approach for treating patients with skin cancer. Esteya electronic brachytherapy mimics proven high dose rate (HDR) brachytherapy by bringing a small X-ray source close to the cancerous site, enabling the local application of radiation for effective treatment. Esteya requires only minimal room shielding, allowing the treatment to occur virtually anywhere patients are seen. The first installations of Esteya in the United States is scheduled to occur in November 2013.  Full Article

Elekta publ AB Receives Order in China
Tuesday, 10 Sep 2013 05:00am EDT 

Elekta publ AB announced that the National Health and Family Planning Commission (NHFPC) of the People’s Republic of China has communicated that Elekta won a tender for seven Leksell Gamma Knife Perfexion units. The deal has a total value of approximately USD 25 million. Elekta was awarded the tender through a central procurement project organized by the NHFPC.  Full Article

Elekta publ AB Announces New Chairman
Tuesday, 3 Sep 2013 12:45pm EDT 

Elekta publ AB announced that Mr. Laurent Leksell has been appointed Chairman of the Board of Directors of the Company. He replaces Mr. Akbar Seddigh, who had declined re-election. Mr. Leksell was previously an ordinary Member of the Company's Board.  Full Article

Elekta publ AB Maintains FY 2013/2014 Financial Guidance
Tuesday, 3 Sep 2013 07:00am EDT 

Elekta publ AB announced that the Company's fiscal year 2013/2014 financial guidance in local currency remains unchanged. Net sales and EBITA are expected to grow by more than 10% in local currency in the fiscal year 2013/2014. For the fiscal year 2012/2013 the Company reported revenue of SEK 10,339.00 million. According to I/B/E/S Estimates analysts on average are expecting Elekta to report revenue of SEK 11,423.29 million for the fiscal year 2013/2014.  Full Article

Elekta AB Announces Correction in Annual Report 2012/2013
Friday, 30 Aug 2013 02:00am EDT 

Elekta AB announced that it has made a correction in the Annual Report 2012/2013. The Company announced that contingent liabilities for the Group on page 86 and in note 29 on page 114 in the annual report 2012/2013 is incorrect. The correct figure should be according to the year-end report May-April 2012/2013 and is SEK 178 million for April 30, 2013 and SEK 68 million for April 30, 2012.  Full Article

Elekta AB's Versa HD System Features Automated Breath Hold Gating for Improved Breast and Lung Radiotherapy
Wednesday, 21 Aug 2013 01:30am EDT 

Elekta AB (Elekta) announced that a new release of Active Breathing Coordinator receives CE marking and 510(k) clearance. Users of Elekta's linear accelerator, Versa HD, can now bring target immobilization to new levels through automated gating with Active Breathing Coordinator. For anatomies affected by respiratory motion, such as lung, liver and breast, Active Breathing Coordinator provides non-invasive, internal immobilization of the target, triggering radiation delivery when anatomy is immobilized. Automated gating with Active Breathing Coordinator recently received CE marking from the European Union and 510(k) clearance from the U.S. Food and Drug Administration (FDA), and in combination with Elekta's Response gating interface, provides additional benefits to both the Versa HD clinically-tailored solutions for treating breast and lung cancers.  Full Article

Elekta bows out of mammoth Brazil tender as price plunges

* Elekta, Varian and Best Theratronics were bidding for contract

Search Stocks